You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
For the maintenance treatment of adult patients with advanced high-grade ovarian, fallopian tube
or primary peritoneal cancer who are in response (complete or partial) following completion of
first-line platinum-based chemotherapy.,As monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed
high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in
response (complete or partial) to platinum-based chemotherapy.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
For the maintenance treatment of adult patients with advanced high-grade ovarian, fallopian tube
or primary peritoneal cancer who are in response (complete or partial) following completion of
first-line platinum-based chemotherapy.,As monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed
high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in
response (complete or partial) to platinum-based chemotherapy.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
For the maintenance treatment of adult patients with advanced high-grade ovarian, fallopian tube
or primary peritoneal cancer who are in response (complete or partial) following completion of
first-line platinum-based chemotherapy.,As monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed
high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in
response (complete or partial) to platinum-based chemotherapy.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
ZEJULA is indicated:,- for the maintenance treatment of adult patients with advanced high-grade ovarian, fallopian tube
or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.,- as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.
Niraparib Tablets, 100 mg, are immediate release, grey, oval-shaped, film coated tablets, debossed with '100' on one side and 'Zejula' on the other side.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on July, 1 2025. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
ZEJULA is indicated:,- for the maintenance treatment of adult patients with advanced high-grade ovarian, fallopian tube
or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.,- as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.
Niraparib Tablets, 100 mg, are immediate release, grey, oval-shaped, film coated tablets, debossed with '100' on one side and 'Zejula' on the other side.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on July, 1 2025. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.
